NCT Number: NCT02828605
Virtual Interactive Platform (VIP) Transplant Research Study
The purpose of this study is to test a tablet-based application called VIP Transplant, devised to improve the recovery experience of patients that have recently had organ transplant surgery. The study will consist of two non-randomized arms: the first arm will consist of usual care and the second will be using the newly developed app for 21 days to replace their in-person visits. Using questionnaires and in-app usage metrics, the research team will track whether patients have a better medical outcome, greater patient satisfaction with care, and greater compliance rates as compared to patients who do not use VIP Transplant to manage their care.
Looking for future studies?
Notify MeKey information
Conditions
Age range
10 year–80 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Early Phase 1
About this study
An organ transplant requires a large time and financial investment for both the patient and provider over the course of a lifetime of follow-up visits and lifestyle monitoring. Patients return to the clinic 2-3 times a week for the first three months after surgery, and then visit the clinic twice a month with labs once a week 91-210 days post surgery. Check-ins for patients without complications occur 1-2 times a year, and these re-evaluations require patients to take time off work and travel to the transplant center often 2 hours away. Dr. David Mulligan, Chief of Transplant at Yale wanted to help patients reduce the time and cost associated with their regular checkups after surgery. Thus, we created VIP Transplant. The Virtual Interactive Platform allows patients to have a secure videoconference with their provider in order to eliminate the need for recurring travel and waiting in congested clinics for a short appointment. It will save patient time and cost to travel to the clinic. The application is integrated into the provider network in order to have a system that supports seamless communication between the patient and provider capabilities.
Research plan:
Dr. Mulligan will contact 8 of his patients who are willing to participate in the study. 4 of the patients will be assigned to the control group and the other 4 will be assigned to the experimental group.
Control group:
On day 1 after their surgery, patient will be asked to fill out a survey on their transplant care. On day 21, patient will be asked to fill out the same survey. The surgeon will be asked to take a survey to evaluate their each patient's progress.
Experimental group:
When the 4 patients attend orientation, patient will each be given the iPad with the VIP Transplant app and shown how to use the app. Patient will then be asked to fill out the survey on day 1 after their surgery and then asked to use VIP Transplant for their transplant care in the following days. Patient will then be asked to fill out the survey again on day 21, at the end of the study. The surgeon will be asked to take a survey to evaluate each of their patient's progress.
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Willing to participate
- Familiarity with English
- Familiarity with iPad usage/technologically adept
Treatment and study plan
Primary outcomes
-
Time to travel from home to Yale New Haven Hospital
Time frame: 30 days
Questionnaire, Scales of 1 to 10
-
Cost to travel from home to Yale New Haven Hospital
Time frame: 30 days
Questionnaire, Scales of 1 to 10
-
Patient Satisfaction with Care
Time frame: 30 days
Questionnaire, Scales of 1 to 10
-
Physician Satisfaction with Care
Time frame: 30 days
Questionnaire, Scales of 1 to 10
Sponsors and collaborators
Lead sponsor
Yale University
Other
Registry information
Important dates
- Study start
- 2016
- Primary completion
- 2016
- Study completion
- 2016
- First posted
- Jul 11, 2016
- Registry last updated
- Sep 28, 2020
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Controlled Terminal Reperfusion With Cold Preservation Solution in the cDCD III Donor
NCT07421726
Multiple Organ Failure, Organ Donor Registration
Bologna, Italy
View Trial DetailsDevelopment, Pilot Testing and Evaluation of the Effectiveness of Immunosuppressive Medication Adherence Care Bundle in Patients Undergoing Solid Organ Transplantation
NCT07447388
Transplant Patients
View Trial DetailsPersonalized Immunological Score for the Prediction of Severe Infectious Events in Immunocompromised Patients and Tailored Management (PERISCOPE)
NCT07379554
Immunocompromised Patients, Infections
Pavia, Lombardy, Italy
View Trial Details